Appropriate Long Term Prescribing and Polypharmacy - PowerPoint PPT Presentation

1 / 22
About This Presentation
Title:

Appropriate Long Term Prescribing and Polypharmacy

Description:

Appropriate Long Term Prescribing and Polypharmacy Alpana Mair Dr Gregor Smith Some Background: The ageing population 62% projected rise in over 65s 2006-31 144% ... – PowerPoint PPT presentation

Number of Views:213
Avg rating:3.0/5.0
Slides: 23
Provided by: DrGrego3
Category:

less

Transcript and Presenter's Notes

Title: Appropriate Long Term Prescribing and Polypharmacy


1
Appropriate Long Term Prescribing and Polypharmacy
  • Alpana Mair
  • Dr Gregor Smith

2
Some Background The ageing population
  • 62 projected rise in over 65s 2006-31
  • 144 projected rise in over 85s 2006-31
  • Increased prevalence of LTC, esp COPD and
    Diabetes
  • 24 projected rise in older people admitted as
    emergencies by 2016
  • Would require an extra 3.5 billion 2031

Audit Scotland
3
Multiple Morbidities
  • Multiple conditions presence of 2 or more LTC
  • Largely the norm but associated with poorer
    outcomes
  • More people in Scotland with MM below 65 years
    than above
  • Develops around 10 years earlier in deprived
    areas
  • Associated with more medical errors

4
Multimorbidity in Scotland
Mercer, Guthrie, Wyke Scottish School of Primary
Care
5
Most people with any long term condition have
multiple conditions in Scotland
Mercer, Guthrie, Wyke Scottish School of Primary
Care
6
Mercer, Guthrie, Wyke Scottish School of Primary
Care
7
Pr. Bruce Guthrie, Dundee
8
Pr. Bruce Guthrie, Dundee
9
Contributory Factors
  • AGE
  • Non age factors that contribute to developing
    polypharmacy include
  • Multiple morbidities
  • Residence in long term care home
  • Hospitalisation, esp repeat episodes of care
  • Patient expectation
  • GP attitude
  • Consultation with several doctors

10
Polypharmacy associated dangers
  • Adverse drug event
  • Confusion
  • Falls
  • Interactions
  • Drug drug Interaction
  • Drug Disease Interaction
  • Poor compliance and concordance

11
Drugs commonly associated with admissions due to
ADR
  • NSAIDs 29.6
  • Diuretics 27.3
  • Warfarin 10.5
  • ACE 7.7
  • Antidepressants 7.1
  • Beta blockers 6.8
  • Opiates 6.0
  • Digoxin 2.9
  • Prednisolone 2.5
  • Clopidogrel 2.4

12
High Risk Combinations
  • NSAID plus any of
  • ACE or ARB diuretic (triple whammy)
  • eGFR lt60
  • Diagnosis heart failure
  • Warfarin
  • Age gt75 without PPI

13
High Risk Combinations
  • Warfarin Plus any of
  • Another antiplatelet
  • NSAID
  • Macrolide
  • Quinolone
  • Metronidazole
  • Azole antifungal

14
High Risk Combinations
  • Heart Failure diagnosis plus any of
  • Glitazone
  • NSAID
  • Tricyclic antidepressant

15
Drugs Poorly Tolerated in the Elderly
  • Digoxin (doses higher than 250mcg)
  • Antipsychotics
  • Tricyclic antidepressants
  • Benzodiazepines
  • Anti cholinergics
  • Phenothiazines
  • Combination painkillers

16
Special considerations
  • Orthostatic hypotension
  • Shared side effects eg sedation, bleeding
  • Diabetic treatment optimal HbA1c
  • Antipsychotic medication
  • Laxatives
  • Shortened life expectancy

17
Drugs which can be associated with rapid
symptomatic decline if stopped
  • ACE inhibitors in heart failure / LVSD
  • Diuretics in heart failure
  • Steroids
  • Drugs for heart rate or rhythm control
  • Anticonvulsants for epilepsy
  • Antidepressant, antipsychotic, mood stabilisers
  • amiodarone
  • Drugs for managing Parkinsons Dis
  • Disease modifying anti-rheumatic drugs

With caution
With specialist advice
18
CEL 36 November 2012
  • Appropriateness of long term prescribing
  • At medicines review
  • On starting new medicines
  • First iteration of National Guidance
  • Aim to improve therapeutic care by reducing the
    risk of adverse drug reactions associated with
    polypharmacy

19
(No Transcript)
20
(No Transcript)
21
GMS Contract 2013 / 14
  • Unique negotiated settlement in Scotland
  • QPQOF High Risk Patients
  • Anticipatory Care Plans
  • Polypharmacy Review
  • Multi-disciplinary approach
  • SPARRA risk score 40-60
  • 0.75 practice popn 1st yr, rising to 1.5 2nd yr

22
Questions?
  • Dr Gregor Smith
  • Alpana Mair
Write a Comment
User Comments (0)
About PowerShow.com